The Pharmacokinetic Characteristics and Safety Between HIP2001 and HGP2001 in Healthy Volunteers

Inclusion Criteria: * 19 kg/m\^2 ≤ BMI \< 28 kg/m\^2, weight \>60kg * 90 mmHg ≤ SBP \<140 mmHg, 50 mmHg ≤ DBP \<900 mmHg * agrees that the person, spouse, or partner uses appropriate medically recognized contraception and does not provide sperm or eggs from the date of administration of the first investigational drug to 7 days after the administration of the last investigational drug. Exclusion Criteria: * A history of hypersensitivity reactions or clinically significant hypersensitivity reactions * A history of gastrointestinal diseases or surgery that may affect the absorption of clinical trial drugs * A history of substance abuse or who test positive for drugs of concern for abuse in the urine drug screening test * Positive results of serological tests * Have taken other investigational drugs or bioequivalence drugs within 6 months before the first administration of the investigational drug * Donated whole blood within 60 days prior to the screening date or donated components within 30 days or received a blood transfusion within 30 days * Have drank more than 210 g/week of alcohol within 30 days before the screening date * Have smoked more than 10 bills/day within 30 days before the screening date * AST, ALT value is more than 2 times the UNL or bilirubin level is more than 1.5 times the UNL, eGFR \< 50 mL/min/1.73m2, Prothrombin (INR) \> 1.31 INR or aPTT \> 39.7 sec * 12-ECG QTc \>450 ms